CSL Seqirus

Liam Sturgess
7 min read

CSL Seqirus, formerly Seqirus, is an Australian multinational vaccine development company. It is a subsidiary of CSL Limited.

History

Seqirus was an exhibitor and sponsor for the OPTIONS IX for the Control of Influenza conference from August 24-28, 2016, in Chicago, Illinois,[1][2] and the Canadian Immunization Conference 2016 from December 6-8, 2016, in Ottawa, Ontario.[3]

Seqirus was a sponsor for the Canadian Immunization Conference 2018 from December 4-6, 2018, at the Shaw Centre in Ottawa, Ontario.[4]

Seqirus was a sponsor for the OPTIONS X for the Control of Influenza conference from August 26-September 1, 2019, in Singapore.[5]

COVID-19

Seqirus was a sponsor for the 2021 AMMI Canada - CACMID Annual Conference,[6] the Canadian Immunization Conference 2021[7] and the 2022 British Columbia Pharmacy Association Annual Conference.[8]

On August 26, 2022, CSL announced that Seqirus was being renamed CSL Seqirus.[9]

CSL Seqirus was an exhibitor and event sponsor at OPTIONS XI for the Control of Influenza from September 26-29, 2022, in Belfast, England.[10][11]

On May 30, 2024, CSL Seqirus announced that it had been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA) to deliver 4.8 million doses of its H5N1 vaccine for the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS) program, its fourth such award.[12] On June 11, the company announced a similar award from the European Commission for 665,000 doses for the Health Emergency Preparedness and Response Authority (HERA).[13]

Organization

Seqirus is a member organization of the Adult Vaccine Access Coalition,[14] Alliance for Biosecurity,[15] BIOTECanada[16] the Biotechnology Innovation Organization (BIO)[17] the European Federation of Pharmaceutical Industries and Associations (EFPIA)[18] and the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA),[19] and a partner organization of Global Health Progress[20] and the National Foundation for Infectious Diseases (NFID).[21]

Personnel

Name Position Notes
Kristina Bradford Senior Project Manager[22] BARDA Industry Day 2018
Randy Deck Senior Director, Pandemic Contracts[22:1] BARDA Industry Day 2018
Phyllis Frosst Global Director, Health Policy[22:2] BARDA Industry Day 2018
Marie Mazur Vice President, Pandemic Response Solutions[22:3] BARDA Industry Day 2018
Melissa Puryear Legal Counsel[22:4] BARDA Industry Day 2018
Martina Scionti Senior Manager, Strategic Planning[22:5] BARDA Industry Day 2018
Gillian Talley Head of Batch Release[22:6] BARDA Industry Day 2018
Beverly Taylor Head of Global Influenza Scientific Policy[23] Multivalent COVID vaccines to help address emergence of variants: CMC and clinical implications

Activities

CSL Seqirus has provided funding to:

  1. OPTIONS IX Supporters. OPTIONS IX. Retrieved July 7, 2017, from https://web.archive.org/web/20170707010655/http://2016.isirv.org/options-ix-supporters ↩︎

  2. Exhibit Opportunities. Options IX. Retrieved July 6, 2017, from https://web.archive.org/web/20170706213219/http://2016.isirv.org/exhibit-opportunities ↩︎

  3. Final Program. (2016, December 6). Canadian Immunization Conference. https://web.archive.org/web/20220320171400/https://www.cpha.ca/sites/default/files/uploads/conferences/2021/cic16-final-program-en.pdf ↩︎

  4. CIC 2018 Final Program. (2018, November). Canadian Immunization Conference. https://web.archive.org/web/20220320193739/https://cic-cci.ca/wp-content/uploads/2018/11/CIC-2018-Final-Program.pdf ↩︎

  5. Options X Supporters. ISIRV 2019. Retrieved October 27, 2022, from https://web.archive.org/web/20221027005431/https://2019.isirv.org/options-x-supporters ↩︎

  6. Sponsorship & Exhibitor Prospectus. (2021, December). Association of Medical Microbiology and Infectious Diseases Canada. https://web.archive.org/web/20230430042311/https://ammi.ca/wp-content/uploads/2021/12/2022-Sponsorship-.Exhibitor-ProspectusFINAL.pdf ↩︎

  7. CIC 2021 Final Program. (2021). Canadian Public Health Association. https://web.archive.org/web/20220422103306/https://www.cpha.ca/sites/default/files/uploads/conferences/2021/cic21-program.pdf ↩︎

  8. Our Sponsors and Prizes. British Columbia Pharmacy Association. Retrieved May 22, 2022, from http://archive.today/2022.05.23-043337/https://www.bcpharmacy.ca/conference/prizes/2022 ↩︎

  9. Coey, S. K. (2022, August 26). CSL to unite all business units, including Seqirus, under the CSL umbrella. Fierce Pharma. https://web.archive.org/web/20220826150412/https://www.fiercepharma.com/marketing/csl-unite-all-business-unit-including-seqirus-under-one-csl-umbrella ↩︎

  10. Meet the Exhibitors. OPTIONS XI. Retrieved October 26, 2022, from https://web.archive.org/web/20221026234139/https://www.optionsxi2022.org.uk/exhibition-and-sponsors2/meet-the-exhibitors ↩︎

  11. Main Sponsors & Supporters. OPTIONS XI. Retrieved October 26, 2022, from https://web.archive.org/web/20221026234119/https://www.optionsxi2022.org.uk/exhibition-and-sponsors2/main-sponsors-and-supporters ↩︎

  12. Dunleavy, K. (2024, May 30). CSL Seqirus scores 4th award from US government for bird flu pandemic preparedness. Fierce Pharma. https://web.archive.org/web/20240812134158/https://www.fiercepharma.com/pharma/csl-seqirus-scores-4th-award-us-government-bird-flu-pandemic-preparedness ↩︎

  13. CSL Seqirus, a Proud Champion of Pandemic Preparedness, Signs an Agreement with the European Commission to Provide Pre-Pandemic Vaccines to the EU. (2024, June 11). CSL. https://web.archive.org/web/20240804012948/https://newsroom.csl.com/2024-06-11-CSL-Seqirus,-a-Proud-Champion-of-Pandemic-Preparedness,-Signs-an-Agreement-with-the-European-Commission-to-Provide-Pre-Pandemic-Vaccines-to-the-EU ↩︎

  14. AVAC Member Organizations. (2021). Adult Vaccine Access Coalition. http://archive.today/2022.07.08-060340/https://adultvaccinesnow.org/our-membership/avac-member-organizations/ ↩︎

  15. Who We Are. Alliance for Biosecurity. Retrieved June 21, 2022, from http://archive.today/2022.06.21-000415/https://web.archive.org/web/20200812033301/https://www.allianceforbiosecurity.com/who-we-are ↩︎

  16. Member Listings. BIOTECanada. Retrieved August 6, 2024, from https://web.archive.org/web/20240806080411/https://www.biotech.ca/about/member-listings/ ↩︎

  17. BIO Member Directory. Biotechnology Innovation Organization. Retrieved September 30, 2022, from https://web.archive.org/web/20220930103715/https://www.bio.org/bio-member-directory ↩︎

  18. Membership. (2022). European Federation of Pharmaceutical Industries and Association. https://web.archive.org/web/20220701031757/https://www.efpia.eu/about-us/membership/ ↩︎

  19. Companies. IFPMA. Retrieved July 1, 2022, from https://web.archive.org/web/20220701150736/https://www.ifpma.org/who-we-are/our-membership/full-members/companies/ ↩︎

  20. Explore Our Collaborations. (2022). Global Health Progress. https://web.archive.org/web/20220403013206/https://globalhealthprogress.org/explore-our-collaborations/ ↩︎

  21. NFID Partner Organizations. (2022, January 6). National Foundation for Infectious Diseases. https://web.archive.org/web/20220716065253/https://www.nfid.org/partners/ ↩︎

  22. BARDA Industry Day 2018 Post Conference Participant List. Biomedical Advanced Research and Development Authority. Retrieved February 27, 2023, from https://web.archive.org/web/20230227080444/https://www.medicalcountermeasures.gov/BARDA/documents/BID2018_ParticipantList.pdf ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎

  23. Granerod, J. (2021, April 14). Workshop Report: COVAX Manufacturing and Clinical Development SWAT Teams Workshop on “Multivalent COVID vaccines to help address emergence of variants: CMC and clinical implications.” The Global Health Network. https://web.archive.org/web/20230322033935/https://media.tghn.org/medialibrary/2021/04/COVAX_VDM_CD_SWAT_TEAM_Workshop_20210414_Multivalent_Vaccines_FINAL_REPORT.pdf ↩︎

  24. How We’re Funded. (2022). Alliance for Aging Research. https://web.archive.org/web/20220715161317/https://www.agingresearch.org/about-us/how-were-funded/ ↩︎

  25. Chung, H., Buchan, S. A., Campigotto, A., Campitelli, M. A., Crowcroft, N. S., Dubey, V., Gubbay, J. B., Karnauchow, T., Katz, K., McGeer, A. J., McNally, J. D., Mubareka, S., Murti, M., Richardson, D. C., Rosella, L. C., Schwartz, K. L., Smieja, M., Zahariadis, G., & Kwong, J. C. (2020). Influenza Vaccine Effectiveness Against All-Cause Mortality Following Laboratory-Confirmed Influenza in Older Adults, 2010–2011 to 2015–2016 Seasons in Ontario, Canada. Clinical Infectious Diseases, 73(5), e1191–e1199. https://doi.org/10.1093/cid/ciaa1862 ↩︎

  26. Corporate partners. Canadian Public Health Association. Retrieved April 19, 2024, from https://web.archive.org/web/20240419085756/https://www.cpha.ca/corporate-partners ↩︎

  27. New Modelling Study concludes “Unvaccinated are a danger to the Vaccinated”; but Real-World Data proves COVID Vaccines INCREASE Risk of Infection by 400%. (2022, April 29). The Exposé. https://web.archive.org/web/20220511165651/https://expose-news.com/2022/04/29/covid-jabs-increase-risk-infection-400percent/ ↩︎

  28. Our Partners in Preventing Influenza. Families Fighting Flu. Retrieved August 1, 2024, from https://web.archive.org/web/20240801141143/https://www.familiesfightingflu.org/donors-sponsors/ ↩︎

  29. The Foundation for Influenza Epidemiology. Global Influenza Hospital Surveillance Network. Retrieved March 28, 2022, from http://archive.today/2022.03.28-193124/https://www.gihsn.org/about-us/the-foundation-for-influenza-epidemiology ↩︎

  30. About Us. Immunisation Coalition. Retrieved December 5, 2021, from https://web.archive.org/web/20210303185121/https://www.immunisationcoalition.org.au/about-us/ ↩︎

  31. Member Organizations. Immunize Canada. Retrieved July 19, 2024, from https://web.archive.org/web/20240719141916/https://immunize.ca/member-organizations ↩︎

  32. Permar, S., Creech, C. B., Edwards, K. M., & Walter, E. B. (2021). Proposals to Accelerate Novel Vaccine Development for Children. Pediatrics, 149(1). https://doi.org/10.1542/peds.2021-054593 ↩︎

  33. Our Partners. Lung Health Foundation. Retrieved June 9, 2022, from http://archive.today/2022.06.09-004346/https://lunghealth.ca/our-partners/ ↩︎

  34. Evans, T., Sadarangani, M., Maguire, J., Zinszer, K., & Kellner, J. (2022). The importance of pediatric vaccination. COVID-19 Immunity Task Force. https://web.archive.org/web/20220424080020/https://www.covid19immunitytaskforce.ca/wp-content/uploads/2022/03/CITF_CanCOVID_6_Pediatric-vaccination_2022_EN_FINAL-2.pdf ↩︎

  35. Waite, N. M., Pereira, J. A., Houle, S. K. D., Gilca, V., & Andrew, M. K. (2021). COVID-19’s impact on willingness to be vaccinated against influenza and COVID-19 during the 2020/2021 season: results from an online survey of Canadian adults 50 years and older. Vaccines, 9(4), 346. https://doi.org/10.3390/vaccines9040346 ↩︎

  36. Lee, N. (2018). ICMJE Form for Disclosure of Potential Conflicts of Interest (pp. 24–26). New England Journal of Medicine. https://web.archive.org/web/20220511231133/https://www.nejm.org/doi/suppl/10.1056/NEJMoa1716197/suppl_file/nejmoa1716197_disclosures.pdf ↩︎

  37. Conflicts of Interest in Pfizer Vaccine Trial. (2022, April 12). ICAN - Informed Consent Action Network. http://archive.today/2022.04.12-231318/https://www.icandecide.org/ican_press/conflicts-of-interest-in-pfizer-vaccine-trial/ ↩︎

  38. Coleman, B. L., Sanderson, R., Haag, M. D. M., & McGovern, I. (2021). Reply to Letter to the Editor by Yin et al. Influenza and Other Respiratory Viruses, 15(6), 828–829. https://doi.org/10.1111/irv.12895 ↩︎

  39. Annual Report 2021. The Task Force for Global Health. Retrieved April 20, 2022, from https://web.archive.org/web/20220215172458/https://www.taskforce.org/annual-report-2021/#section_2 ↩︎

  40. About Us. Vaccines4Life. Retrieved July 15, 2022, from https://web.archive.org/web/20220715204513/https://www.vaccines4life.com/about-us/ ↩︎

  41. Voluntary contributions by fund and by contributor, 2021. (2022). World Health Organization. https://web.archive.org/web/20220516042059/https://apps.who.int/gb/ebwha/pdf_files/WHA75/A75_INF5-en.pdf ↩︎

Profiles
About the author
Liam Sturgess

Liam Sturgess

Liam Sturgess is a Canadian writer, researcher and investigative reporter focused on issues of human rights and civil liberties, with a particular interest in the COVID-19 pandemic. He is the founder of White Rose Intelligence.

Read next

ARC Foundation

CBA Task Force on Justice Issues Arising from COVID-19

Action Committee on Court Operations in Response to COVID-19

Decentralized Radical Autonomous Search Team Investigating COVID-19

The Courage to Face COVID-19

Knowledge is Freedom

Research and intelligence in defense of liberty

White Rose Intelligence

Great! You’ve successfully signed up.

Welcome back! You've successfully signed in.

You've successfully subscribed to White Rose Intelligence.

Your link has expired.

Success! Check your email for magic link to sign-in.

Success! Your billing info has been updated.

Your billing was not updated.